PARP1 and left ventricular hypertrophy: Moreover, another PARP-1 inhibitor, L-2286, can not only prevent the development of left ventricular hypertrophy in SHRs, but also modulate mitochondrial dynamics and biogenesis, indicating that PARP-1 may be a therapeutic target in hypertensive cardiac hypertrophy.